HealthLumen

Today is #WorldDiabetesDay, an important opportunity to raise awareness of #diabetes, which impacts over 530 million people worldwide. With diabetes rates continuing to climb, what policies could help to turn the tide? At HealthLumen, our recent research commissioned by Nesta identified several policies that could lead to substantial reductions in type 2 diabetes cases. These policies, which include implementing food advertising restrictions and a sugar and salt tax, show significant potential over the 5-year period modelled. Read more about the research here>> https://lnkd.in/evVcugxk #WDD #diabetesawareness #obesity #healthpolicy

Nesta’s Blueprint for halving the prevalence of obesity in the UK by 2030, incorporating HealthLumen’s modelling work on the health and economic impact of 32 obesity policies, will be presented at a live webinar on Tuesday 3rd December at 12.00 GMT.

Obesity is perhaps the biggest public health crisis affecting the UK (and many other countries) costing UK society over £98 billion a year, with obesity rates having doubled since the 1990s. Nesta – the UK’s innovation agency for social good – have created a Blueprint for halving the prevalence of obesity in the UK by 2030, and commissioned HealthLumen to model the health and economic impact of 32 obesity policies. For the first time, it is possible to identify the most effective routes to pursue and at what scale, based on the strength of the evidence about what works and how much each would cost to implement, with fiscal policies expected to be particularly cost beneficial. https://lnkd.in/eENxJKM4 #obesity #healthpolicy

🧑🔬 Amanda Hayward, Head of Global Business Development presented our research, in partnership with HealthLumen, on quantifying the proportion of women at risk of an FNAIT pregnancy in diverse populations in the United States at NORD today.     The study reveals key findings on fetal/neonatal alloimmune thrombocytopenia (FNAIT) risk across diverse ancestries for the first time.     ˃˃ Using genetic data, researchers found that nearly 20,000 pregnancies in the U.S. are at higher risk for FNAIT each year—far more than previously estimated.    ˃˃ The study highlights that non-White populations also carry significant FNAIT risk, challenging past assumptions.    ˃˃ These findings make a compelling case for universal screening of pregnant women for FNAIT risk, regardless of race or ethnicity, and we’re proud to play a part in advocating for a future where this is the norm.     #HealthEquity #FNAIT #MaternalHealth #NORD #NORD24  

"Approximately 80% of rare diseases have a genetic origin. Consequently, genetic databases enable the allele frequencies of variants associated with a particular rare genetic disease to be calculated and stratified by ancestry. These can then be scaled using population data to produce rare genetic disease prevalence figures for a population of interest." In our latest blog post, HealthLumen shares how leveraging genetic databases can optimize decision-making at each stage of drug development. Read it here: https://lnkd.in/gXbzKYfy Request a free epidemiological evaluation today: https://lnkd.in/gUJKPx-s

Although rare disease affect a significant portion of the population, most of them lack approved therapies, presenting a significant unmet need. "One major challenge in addressing this gap is the difficulty in accurately estimating patient population sizes, which can disrupt the route to market for rare disease therapeutics." Learn how large genetic databases are providing a promising solution to these challenges, in our recent blog post with HealthLumen: https://lnkd.in/gXbzKYfy Request a free epidemiological evaluation today: https://lnkd.in/gUJKPx-s

Learn how leveraging genetic databases can optimize decision-making at each stage of drug development, in our recent blog post with HealthLumen: https://lnkd.in/gXbzKYfy Also, request a free epidemiological evaluation today: https://lnkd.in/gUJKPx-s

HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year. Starting off with the PCD Research Rare Disease Industry Accelerator Day on 1st October at The Francis Crick Institute.   Reach out to us today to book in a meeting at one of these upcoming conferences and we look forward to connecting with you there. https://lnkd.in/ejV9g3du #RareDisease #OrphanDrug #DrugDevelopment #PatientAccess #pcd 

"Rare diseases, though individually rare, collectively affect 3.5–5.9% of the global population, which equates to 263–446 million persons affected globally at any point in time [1]. Approximately 95% of these conditions lack approved therapies, presenting a significant unmet need" In our latest blog post with HealthLumen, we discuss how leveraging genetic databases can optimize decision-making at each stage of drug development. Read it now: https://lnkd.in/gXbzKYfy [1}: https://lnkd.in/dmUWPgP